Identification of Staphylococcus Aureus α-hemolysin as a protein drug that is secreted by anticancer bacteria and rapidly kills cancer cells

Biotechnology and Bioengineering

Volumn 111, Issue 6, 2014, Pages 1233-1245

  Swofford, Charles A ^a   St Jean, Adam T ^a,b   Panteli, Jan T ^a   Brentzel, Zachary J ^a   Forbes, Neil S ^a  

^a University of Massachusetts   (United States)

^b University of New Hampshire   (United States)

Author keywords

Bacterial anticancer therapy; Cancer; Localized drug delivery; Staphylococcus; Toxin screen; Triple negative breast cancer; hemolysin

Indexed keywords

BACTERIA; BLOOD; CELL DEATH; CELL MEMBRANES; CLONING; DISEASES; DRUG DELIVERY; ENZYME INHIBITION; ESCHERICHIA COLI; TUMORS;

ANTI-CANCER PROTEINS; ANTI-CANCER THERAPIES; CANCER; MAMMARY CARCINOMA CELL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; TRIPLE-NEGATIVE BREAST CANCERS;

PROTEINS;

ALPHA HEMOLYSIN; ANTINEOPLASTIC AGENT; AZURIN; BACTERIAL PROTEIN; CYTOLETHAL DISTENDING TOXIN; DERMONECROTIC TOXIN; PHOSPHOLIPASE C; PSEUDOMONAS AERUGINOSA EXOTOXIN A; PSEUDOMONAS EXOTOXIN; STAPHYLOCOCCUS AUREUS ALPHA HEMOLYSIN; UNCLASSIFIED DRUG; BACTERIAL TOXIN; HEMOLYSIN; STAPHYLOCOCCAL ALPHA-TOXIN;

APOPTOSIS; ARTICLE; BACTERIAL CELL; BACTERIUM CULTURE; BREAST CARCINOMA; CARCINOMA CELL LINE; CELL DEATH; CELL LYSATE; CELL MEMBRANE; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CODON; CONTROLLED STUDY; CYTOPLASM; ESCHERICHIA COLI; HUMAN; HUMAN CELL; LC 50; MAMMAL CELL; NONHUMAN; PROTEIN TARGETING; PSEUDOMONAS AERUGINOSA; SALMONELLA; STAPHYLOCOCCUS AUREUS; SUPERNATANT; TIME LAPSE IMAGING; VECTOR CONTROL; CELL SHAPE; DRUG EFFECTS; MCF 7 CELL LINE; TUMOR CELL CULTURE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MAMMALIA; PSEUDOMONAS AERUGINOSA; SALMONELLA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CELL SHAPE; CELL SURVIVAL; HEMOLYSIN PROTEINS; HUMANS; MCF-7 CELLS; TIME-LAPSE IMAGING; TUMOR CELLS, CULTURED;

EID: 84899625883     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25184     Document Type: Article

References (52)

1. Aktories K. 2011. Bacterial protein toxins that modify host regulatory GTPases. Nat Rev Microbiol 9:487-498.
2. Alouf JE, Popoff MR. 2006. The comprehensive sourcebook of bacterial protein toxins third. London: Elsevier.
3. Baneyx F, Mujacic M. 2004. Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol 22:1399-1408.
4. Bernardes N, Ribeiro AS, Abreu S, Mota B, Matos RG, Arraiano CM, Seruca R, Paredes J, Fialho AM. 2013. The bacterial protein azurin impairs invasion and FAK/Src signaling in P-cadherin-overexpressing breast cancer cell models. PLoS ONE 8:e69023.
5. Berube BJ, Bubeck Wardenburg J. 2013. Staphylococcus aureus α-toxin: Nearly a century of intrigue. Toxins (Basel) 5:1140-1166.
6. Bischofberger M, Gonzalez MR, van der Goot FG. 2009. Membrane injury by pore-forming proteins. Curr Opin Cell Biol 21:589-595.
7. Bogumil D, Dagan T. 2012. Cumulative impact of chaperone-mediated folding on genome evolution. Biochemistry 51:9941-9953.
8. Chen G, Wei D-P, Jia L-J, Tang B, Shu L, Zhang K, Xu Y, Gao J, Huang X-F, Jiang W-H, Hu Q-G, Huang Y, Wu Q, Sun Z-H, Zhang J-F, Hua Z-C. 2009. Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity. Cancer Sci 100:2437-2443.
9. Dai Y, Toley BJ, Swofford CA, Forbes NS. 2012. Construction of an inducible cell-communication system that amplifies Salmonella gene expression in tumor tissue. Biotechnol Bioeng 110:1769-1781.
10. Davies E, Hiscox S. 2011. New therapeutic approaches in breast cancer. Maturitas 68:121-128.
11. Dinges MM, Orwin PM, Schlievert PM. 2000. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 13:16-34; table of contents.
12. Elwell CA, Dreyfus LA. 2000. DNase I homologous residues in CdtB are critical for cytolethal distending toxin-mediated cell cycle arrest. Mol Microbiol 37:952-963.
13. Forbes NS. 2010. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 10:785-794.
14. Forbes NS, Munn LL, Fukumura D, Jain RK. 2003. Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res 63:5188-5193.
15. Ganai S, Arenas RB, Forbes NS. 2009. Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer 101:1683-1691.
16. Ganai S, Arenas RB, Sauer JP, Bentley B, Forbes NS. 2011. In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther 18:457-466.
17. Guzman LM, Belin D, Carson MJ, Beckwith J. 1995. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J Bacteriol 177:4121-4130.
18. Isakoff SJ. 2010. Triple-negative breast cancer: Role of specific chemotherapy agents. Cancer J 16:53-61.
19. Jain RK. 1998. The next frontier of molecular medicine: Delivery of therapeutics. Nat Med 4:655-657.
20. Jia L-J, Wei D-P, Sun Q-M, Huang Y, Wu Q, Hua Z-C. 2007. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models. Cancer Sci 98:1107-1112.
21. Jiang S-N, Phan TX, Nam T-K, Nguyen VH, Kim H-S, Bom H-S, Choy HE, Hong Y, Min J-J. 2010. Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy. Mol Ther 18:635-642.
22. Johansson D, Johansson A, Behnam-Motlagh P. 2008. alpha-Toxin of Staphylococcus aureus overcomes acquired cisplatin-resistance in malignant mesothelioma cells. Cancer Lett 265:67-75.
23. Kasinskas RW, Forbes NS. 2006. Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng 94:710-721.
24. Kasinskas RW, Forbes NS. 2007. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res 67:3201-3209.
25. Kuan CT, Wang QC, Pastan I. 1994. Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. J Biol Chem 269:7610-7616.
26. Lee C-H, Wu C-L, Shiau A-L. 2008. Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma. Int J Cancer 122:930-935.
27. Lemichez E, Barbieri JT. 2013. General aspects and recent advances on bacterial protein toxins. Cold Spring Harb Perspect Med 3:a013573.
28. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. 2008. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281.
29. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. 2008. IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther 15:787-794.
30. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Luo X, Miller SI, Zheng L, King I, Pawelek JM, Bermudes D. 1999. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 17:37-41.
31. Luo X, Li Z, Lin S, Le T, Ittensohn M, Bermudes D, Runyab JD, Shen SY, Chen J, King IC, Zheng LM. 2001. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res 12:501-508.
32. Majno G, Joris I. 1995. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 146:3-15.
33. Minchinton AI, Tannock IF. 2006. Drug penetration in solid tumours. Nat Rev Cancer 6:583-592.
34. Nagakura C, Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M, Hoffman RM. 2009. Efficacy of a genetically modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. Anticancer Res 29:1873-1878.
35. Nguyen VH, Kim H-S, Ha J-M, Hong Y, Choy HE, Min J-J. 2010. Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res 70:18-23.
36. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Bosmans E, Anné J, Lambin P. 2001. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2Gy irradiation. Gene Ther 8:1197-1201.
37. Panchal RG, Smart ML, Bowser DN, Williams DA, Petrou S. 2002. Pore-forming proteins and their application in biotechnology. Curr Pharm Biotechnol 3:99-115.
38. Pawelek JM, Low KB, Bermudes D. 1997. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57:4537-4544.
39. Peek JA, Taylor RK. 1992. Characterization of a periplasmic thiol:disulfide interchange protein required for the functional maturation of secreted virulence factors of Vibrio cholerae. Proc Natl Acad Sci USA 89:6210-6214.
40. Rocha EPC, Danchin A. 2004. An analysis of determinants of amino acids substitution rates in bacterial proteins. Mol Biol Evol 21:108-116.
41. Ryan RM, Green J, Williams PJ, Tazzyman S, Hunt S, Harmey JH, Kehoe SC, Lewis CE. 2009. Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Ther 16:329-339.
42. Saraste A, Pulkki K. 2000. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 45:528-537.
43. St Jean AT, Zhang M, Forbes NS. 2008. Bacterial therapies: Completing the cancer treatment toolbox. Curr Opin Biotechnol 19:511-517.
44. Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, MacEwen EG. 2005. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: Phase I evaluation. Clin Cancer Res 11:4827-4834.
45. Thelestam M, Möllby R. 1983. Survival of cultured cells after functional and structural disorganization of plasma membrane by bacterial haemolysins and phospholipases. Toxicon 21:805-815.
46. Theys J, Pennington O, Dubois L, Anlezark G, Vaughan T, Mengesha A, Landuyt W, Anné J, Burke PJ, Dûrre P, Wouters BG, Minton NP, Lambin P. 2006. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer 95:1212-1219.
47. Vandana S, Raje M, Krishnasastry MV. 1997. The role of the amino terminus in the kinetics and assembly of alpha-hemolysin of Staphylococcus aureus. J Biol Chem 272:24858-24863.
48. Wang X, Zhou C, Qiu G, Yang Y, Yan D, Xing T, Fan J, Tang H, Peng Z. 2012. Phospholipase C epsilon plays a suppressive role in incidence of colorectal cancer. Med Oncol 29:1051-1058.
49. Wolf P, Elsässer-Beile U. 2009. Pseudomonas exotoxin A: From virulence factor to anti-cancer agent. Int J Med Microbiol 299:161-176.
50. Yamada T, Hiraoka Y, Ikehata M, Kimbara K, Avner BS, Das Gupta TK, Chakrabarty AM. 2004. Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin. Proc Natl Acad Sci USA 101:4770-4775.
51. Yoon D-S, Wersto RP, Zhou W, Chrest FJ, Garrett ES, Kwon TK, Gabrielson E. 2002. Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am J Pathol 161:391-397.
52. Zhao M, Geller J, Ma H, Yang M, Penman S, Hoffman RM. 2007. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA 104:10170-10174.